Billionaires send Ganymed racing through clinic
Authored by James Sheppard The Germany biotechnology company Ganymed has announced that it had successfully raised $60m in a new venture round to advance the ongoing phase IIa and phase IIb study of...
View ArticleCovagen raises $63m for targeted antibody work
Authored by Karl Simpson The Swiss biotechnology company Covagen announced that it had successfully completed a second round of funding (series B) by raising $63m. The funding came from existing...
View ArticleERYTECH makes new appointment to Board of Directors
Authored by Karl Simpson ERYTECH has announced that Vanessa Mailer will join its Board of Directors in replacement for Dr. Alain Munoz as representative of Idinvest. Vanessa Mailer is a partner with...
View ArticleDr Michael Pellini – Foundation Medicine – Executive Leadership Series
Authored by Karl Simpson At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Dr Michael...
View ArticleVersartis follows CFO hire with Chairman appointment
Authored by Karl Simpson In December, Versartis Inc. named Joshua Brumm as its first Chief Financial Officer (CFO). Mr. Brumm will oversee the company’s financial operations as well as investor...
View ArticleWilson Therapeutics Raises $40m to advance development program
Authored by James Sheppard The Stockholm based rare disease biotech, Wilson Therapeutics, announced that it had raises $40m in series B funding. The funding was co-led by new investors Abingworth LLP...
View ArticleAvalanche Biotechnologies raises $102m in up-sized IPO
Authored by James Sheppard The California based gene therapy company Avalanche Biotechnologies announced that it has raised $102m from its initial public offering (IPO). The company will be listed on...
View ArticleBicycle Therapeutics raises $32m for oncology assets
Authored by James Sheppard The Cambridge based biotech Bicycle Therapeutics announced that it raised $32m in venture financing to continue developing the company’s assets in oncology and ophthalmology....
View ArticleBiotechnology must embrace a more diverse future of leadership
Authored by Karl Simpson When you talk to biotech entrepreneurs and sector investors, the topic of management and leadership is one that often features very strongly as the critical success factor....
View ArticleWomen Currently only 10% of Biotech Boards, Gender Study Shows
Authored by Karl Simpson In a new research study into gender diversity in biotech leadership, the findings convey a picture of significant male dominance in biotech boardroom. The research conducted by...
View ArticleBiotech Investors Follow Pattern in Funding and Hiring Executives
Written by: Karl Simpson To be blunt, biotechnology ventures require lots of capital, and although alternative funding sources are now more accessible, money has traditionally come from the venture...
View ArticleKuros Biosurgery Closes Round at CHF 20m
Kuros Biosurgery AG, a biotechnology company developing novel biomaterials and bioactive-biomaterial combination products and focused in therapeutic areas covering sealants and orthobiologics, today...
View ArticleClarus Ventures Strengthens Investment Team with 3 Hires
Clarus Ventures, a life sciences investment firm, has appointed Kiran Reddy and Robert DeBenedetto to Venture Partner, and Lazar Dimitrov to Associate. Based in the firm’s Cambridge, Mass. office,...
View ArticleSV Life Sciences Appoints Joshua Resnick as Partner
SV Life Sciences (SVLS), a life sciences venture capital firm with offices in Boston, London and San Francisco, has appointed Joshua Resnick as Partner. Based in Boston, Resnick joins SVLS’ biotech...
View Article
